Rhenium-Skin Cancer Therapy (SCT) for the Treatment of Non-Melanoma Skin Cancer.

Inclusion Criteria:

1. Stage I or II BCC or SCC (SCC Well to Moderately Differentiated), and clinicallynode negative disease

2. Confirmed Histology, and with depth of lesion noted

3. Subjects with up to 3 lesions suitable to enter the study (subjects with more than 3lesions are not excluded from the study, however 3 target lesions are determined forstudy evaluation only.)

4. Subjects able and willing to comply with the requirements of the study

5. Age >=18 years

6. Informed Consent signed by the subject consenting to undergo the study

7. Lesions up to 8cm2

8. Lesions with a depth up to 3mm confirmed on biopsy report AND deemed appropriateclinically by treating clinician

9. Subjects who are not deemed suitable for surgery, for example due to tumourlocation, performance status or other comorbidities as deemed relevant by thetreating clinician

10. Patients who may have declined Surgery and/or fractionated Radiation Therapy

Exclusion Criteria:

1. Inability to personally provide written informed consent or to understand andcollaborate throughout the study

2. Inability or unwillingness to comply with study requirements

3. Prior treatment with surgery or radiation therapy for their target lesion(s)

4. Depth of lesion greater than 3mm as defined by Biopsy and/or clinical assessment

5. Lupus and Scleroderma

6. Basal cell naevus syndrome, xeroderma, vitiligo and albinism

7. Prior laser at the tumour site

8. Malignant melanoma systemic therapy ongoing

9. Any ongoing treatment for malignancy, or in the last 4 weeks prior to study entry

10. A tumour affecting nerves or bony structures

11. Clinical concern of metastatic disease

12. Pregnancy and/or Lactation

13. Pathological exclusions: Perineural Invasion, Lymphovascular invasion

14. Anatomical exclusions: NMSC's of the Medial canthus, eyelid margin (upper andlower), Vermillion lip